DOCSLIB.ORG

Update in Cancer Chemotherapy: Genitourinary Tract Cancer, Part 4: Testicular Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Update in Cancer Chemotherapy: Genitourinary Tract Cancer, Part 4: Testicular Cancer UPDATE IN CANCER CHEMOTHERAPY: GENITOURINARY TRACT CANCER, PART 4: TESTICULAR CANCER Jane C. Wright, MD Valhalla, New York An update of the state of the art of cancer che- is associated with accurate serum markers: human motherapeutic treatment of genitourinary tract chorionic gonadotropin (HCG) and a-fetoprotein cancer is described in this multi-part series: in- (AFP). In addition, in these cancers it is possible to cluded are cancers of the kidney, bladder, pros- convert a chemotherapy-produced partial remission tate, testicle, ovary, uterus, vulva, and gestational into a complete remission by the surgical removal of trophoblastic neoplasms. Part 4 is a review of the residual disease. Of further interest is the change treatments for cancer of the testicles. that occurs in the histology of these tumors from an Testicular cancer is highly curable and re- aggressive embryonal-cell carcinoma in the orchiec- sponds well to both surgery and chemotherapy. tomy specimen to a mature teratoma in the surgical Patients with stage I and stage 11 nonsemino- specimen following the administration of chemo- matous germ-cell tumors may be cured by sur- therapy. Of most significance is that testicular cancer gery alone or in combination with chemotherapy. has become a highly curable disease that now repre- In patients with pathologic stage 11 disease, the sents a model for a curable neoplasm. use of adjuvant chemotherapy with two courses While the cause of testicular cancer is unknown, of platinum-based combination drugs has been there are certain conditions associated with an in- successful in preventing relapse. Further refine- creased appearance of these tumors, such as in the ments in management and research could banish testes following mumps orchitis and in the atrophic the problem of testicular cancer. cryptorchid testes (undescended testes) even after or- chiopexy. In the undescended testes, the risk of de- veloping cancer is 40 times greater than in the normal descended scrotal testes. Testicular cancers are rare tumors that account for There have been major differences of opinion and only 1 percent of all the cancers that occur in men controversy concerning the topic of the histologic and have an annual incidence of 2.3 persons per classification of testicular tumors. Since 1940 there 100,000 in the United States. These tumors are of have been six major reclassifications. There are four major importance because they are the most common classical histologic cell types in the testicular tumor: carcinomas in young men in the 15- to 35-year-old seminoma, embryonal carcinoma, teratoma, and age group. Unlike many neoplasms, testicular cancer choriocarcinoma. Of the four types 40 percent are seminomas, 15 to 20 percent are embryonal carci- nomas, 20 to 25 percent are teratocarcinomas, and 1 Dr. Wright is Professor Emeritus of Surgery, New York Medical percent are choriocarcinoma. A comparison of clas- College, Valhalla, New York. Requests for reprints should be addressed to Dr. Jane C. Wright, 315 West End Avenue, New sifications of testicular germ-cell tumors is shown in York, NY 10023. Table 14.204 In the British system, all nonsemino- JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, VOL. 80, NO. 4, 1988 425 CANCER CHEMOTHERAPY UPDATE TABLE 14. CLASSIFICATIONS OF TESTICULAR GERM-CELL TUMORS* British Testicular2O8 Dixon and Moore201 Mostofi and Price206 World Health Organization207 Tumor Panel Seminoma Tumors of one histologic Tumors of one histologic type type Seminoma (typical) Seminoma Seminoma Spermatocytic seminoma Spermatocytic seminoma Spermatocytic seminoma Anaplastic seminoma** Embryonal carcinoma Enbryonal carcinoma Embryonal carcinoma Malignant teratoma, Polyembryoma Polyembryoma undifferentiated Adult Teratoma, adult Teratoma Teratoma Teratoma, differentiated Mature Mature Immature Immature With malignant With malignant transformation change*** Embryonal carcinoma ju- Yolk sac tumor (embryonal car- Yolk sac tumor venile cinoma, juvenile type, en- dodermal sinus tumor) Choriocarcinoma Choriocarcinoma Choriocarcinoma Tumors of more than Tumors of more than one histo- one histologic type logic type Teratoma with em- Embryonal carcinoma Embryonal carcinoma with tera- Malignant teratoma, in- bryonal carcinoma with teratoma ("ter- toma ("teratocarcinoma") termediate ("teratocarci- atocarcinoma") noma") Specify types Choriocarcinoma and any other Malignant teratoma tro- types (specify type) phoblastic Specify types Other combinations (specify) "Combined tumor" when seminoma is present * From Einhorn LH204; excluding extratubular germ-cell neoplasia. ** This term has been discarded in a more recent formulation. *** Refers to malignant areas independent of seminoma, embryonal carcinoma, or choriocarcinoma. matous germ-cell tumors are malignant teratomas of pain in the testes, especially after "trauma" in the one type or another. In the American system, the young adult. Other signs and symptoms are related term embryonal carcinoma indicates a tumor that to metastatic disease and include abdominal mass, appears as the most undifferentiated form of tera- adenopathy, gynecomastia, headaches, and other toma. The importance of the classification system is central nervous system symptoms. that in most of the large series of cases of testicular The diagnosis of testicular cancer is confirmed tumors treated by radiation therapy, the tumors are usually by orchiectomy, which is performed surgically classified according to the British system; however, through a high inguinal approach that allows for de- in the reports of the large surgical series, the tumors livery of the testes without contamination of the ad- are classified according to the American system.205 jacent scrotal tissue. If the diagnosis is made, a com- Ninety-six percent oftesticular tumors are malignant plete workup is done to stage the disease. This workup germ-cell tumors, and for the purposes of treatment includes chest films, tomography (ifthe serum mark- they are considered as either seminomas or as non- ers are elevated), intravenous pyelogram, abdominal seminomas. sonography, computerized axial tomography, serum The presenting sign of testicular cancer is usually a-fetoprotein, and ,B-subunit HCG. a-Fetoprotein, a a painless scrotal mass, and there may be swelling or serum protein in the embryo, is found in approxi- 426 JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, VOL. 80, NO. 4, 1988 CANCER CHEMOTHERAPY UPDATE mately 70 percent of patients with teratocarcinomas percent false-negative rate,2"' including the scans and and embryonal-cell carcinomas. In addition, AFP is serum markers. found in 70 percent ofpatients with hepatomas and, occasionally, in cases of other gastrointestinal tract carcinomas (eg, pancreas, gallbladder, etc). Because TREATMENT the half-life ofAFP is five days, it is necessary to wait Surgery, radiotherapy, and chemotherapy are all more than five days after orchiectomy for the serum useful in the treatment of patients with testicular tu- level to return to normal to be certain that the patient mors. Coordinated treatment with these modalities does not have metastatic disease. Human chorionic has led to the marked improvement in the survival gonadotropin, a glycoprotein, is composed of two rates over the past 25 years. polypeptide chains known as alpha and beta. The ,3 subunit is unlike the ,3 subunits of luteinizing hor- mone, follicle-stimulating hormone, and thyroid- Surgery stimulating hormone, but the a subunit is similar to Surgery is used in the treatment of the primary the a subunits ofthese three hormones. Patients with tumor, for regional lymphatic metastasis and, on oc- germ-cell tumors are best followed by radioimmu- casion, for the management of distant metastases. noassays using antibodies against the ,B subunit. The After the diagnosis is made, the primary tumor should metabolic half-life ofHCG is 30 hours. a-Fetoprotein be removed immediately. Radical orchiectomy is the or HCG is positive in 85 percent ofpatients with tes- procedure ofchoice for the early stages ofthe disease ticular tumors; however, these markers should not be because it removes all ofthe tumor. The orchiectomy relied on alone for staging. includes a high-inguinal ligation of the vas deferens and spermatic vessels, a complete removal of the contents of the inguinal canal, and removal of the STAGING OF TESTICULAR TUMORS testis and its adnexa, including the parietal layer of the tunica vaginalis. Removal ofthe entire testis per- Testicular tumors are staged from I to III according mits serial sections to determine the histopathologic to the progression ofthe disease. In stage I, the disease diagnosis. The cure rate for seminomas is in the 90 is confined to one testis IA. In stage IB, the disease is to 95 percent range with primary orchiectomy fol- as in IA, with the addition of histologic evidence of lowed by postoperative radiation therapy; however, metastases to the iliac or para-aortic nodes. In stage for nonseminomatous tumors, the cure rate has II disease, there is clinical or radiographic evidence ranged from 15 to 50 percent. of metastases to the femoral, inguinal, iliac, or para- Because testicular cancers usually spread first by aortic nodes, but no evidence of disease above the the lymphatics to the retroperitoneal lymph nodes, diaphragm. There has been controversy over whether many clinical groups remove the nodes as well. The exploratory laparotomy and node dissection should radical retroperitoneal lymphadenectomy (RPLND) become a mandatory staging procedure
Load more

Recommended publications
  • Gonadal (Testicular and Ovarian Tumors)
    Gonadal (Testicular and Ovarian Tumors) Gonadal (Testicular and Ovarian Tumors) Authors: Ayda G. Nambayan, DSN, RN, St. Jude Children’s Research Hospital Erin Gafford, Pediatric Oncology Education Student, St. Jude Children’s Research Hospital; Nursing Student, School of Nursing, Union University Content Reviewed by: Guillermo L. Chantada, MD, Hospital JP Garrahan, Buenos Aires, Argentina Cure4Kids Release Date: 1 September 2006 At 4 weeks gestation, germ cells begin to develop in the yolk sac in an undifferentiated state. These primordial germ cells migrate to the gonadal ridge by the 6th week of gestation, and descend into the pelvis or scrotal sac.This migratory route explains the midline location of most extra-gonadal germ cell tumors (intracranial, mediastinal, retroperitoneal or sacrococcygeal). (A -1 ) Germ cell neoplasms arise either from the primordial germ cells (gonadal) or indirectly through embryonic or extra-embryonic differentiation (extra-gonadal). The stromal tumors arise from the primitive sex cords of either the ovary or the testicles, and the rare epithelial tumors arise from the coelomic epithelium that have undergone neoplastic transformations. Though the morphology of each type of germ cell tumor is similar in all locations (whether gonadal or extragonadal), the morphologic type and biological characteristics vary depending on the site of origin and age of the patient. There are three (A – 2) biologically distinct subsets of germ cell tumors: - tumors of the adolescent testis and ovary - extragonadal germ cell tumors of older children - tumors of infants and young children Testicular Germ Cell Tumors: Approximately 7% of all germ cell tumors are testicular and 75% of all (A – 3) testicular tumors have a germ cell origin.
    [Show full text]
  • Pediatric Suprasellar Germ Cell Tumors: a Clinical and Radiographic Review of Solitary Vs
    cancers Article Pediatric Suprasellar Germ Cell Tumors: A Clinical and Radiographic Review of Solitary vs. Bifocal Tumors and Its Therapeutic Implications Darian R. Esfahani 1 , Tord Alden 1,2, Arthur DiPatri 1,2, Guifa Xi 1,2, Stewart Goldman 3 and Tadanori Tomita 1,2,* 1 Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL 60611, USA; [email protected] (D.R.E.); [email protected] (T.A.); [email protected] (A.D.); [email protected] (G.X.) 2 Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA 3 Division of Hematology, Oncology, Neuro-Oncology & Stem Cell Transplantation, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL 60611, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-312-2274220 Received: 7 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Simple Summary: Bifocal suprasellar germ cell tumors are a unique type of an uncommon brain tumor in children. Compared to other germ cell tumors in the brain, bifocal tumors are poorly understood and have a bad prognosis. In this paper we explore features that predict which children will have good outcomes and which will not. This is important for the research community because it can help physicians decide what type of radiation treatment is best to treat these children. Our study shows that bifocal tumors have a unique appearance on magnetic resonance imaging (MRI) compared to other germ cell tumors. Children with bifocal tumors are more likely to be male, have tumors that come back sooner, and cause death sooner.
    [Show full text]
  • Pure Choriocarcinoma of the Ovary: a Case Report
    Case Report J Gynecol Oncol Vol. 22, No. 2:135-139 pISSN 2005-0380 DOI:10.3802/jgo.2011.22.2.135 eISSN 2005-0399 Pure choriocarcinoma of the ovary: a case report Lin Lv1, Kaixuan Yang2, Hai Wu1, Jiangyan Lou1, Zhilan Peng1 Departments of 1Obstetrics and Gynecology and 2Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China Pure ovarian choriocarcinomas are extremely rare and aggressive tumors which are gestational or non­gestational in origin. Due to the rarity of the tumor, there is a lack of information on the clinicopathologic features, diagnosis, and treatment. We report a case of a pure ovarian choriocarcinoma, likely of non­gestational origin, treated by cytoreductive surgery in combination with post­operative chemotherapy. The patient was free of disease after a 12­month follow­up. Keywords: Choriocarcinoma, Non­gestational, Ovary INTRODUCTION CASE REPORT Pure ovarian choriocarcinomas are extremely rare malignan­ A 48­year­old woman was admitted to our department cies which are of gestational or non­gestational in origin. with a 6­month history of irregular vaginal bleeding and a The gestational type may arise from an ectopic ovarian pre­ 1­month history of a palpable abdominal mass. She had a gnancy or present as a metastasis from a uterine or tubal nor mal vaginal delivery at 26 years of age and had no recent choriocarcinoma, while the non­gestational type is a rare history of normal pregnancies, molar gestations, or abortions. germ cell tumor with trophoblastic differentiation. The esti­ The physical examination revealed abdominal tenderness and mated incidence of gestational ovarian choriocarcinomas a fixed mass arising from the pelvis to 3 cm below the um­ is 1 in 369 million pregnancies [1].
    [Show full text]
  • LEUKERAN 3 (Chlorambucil) 4 Tablets 5
    1 PRESCRIBING INFORMATION ® 2 LEUKERAN 3 (chlorambucil) 4 Tablets 5 6 WARNING 7 LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a 8 carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. 9 Chlorambucil produces human infertility (see WARNINGS and PRECAUTIONS). 10 DESCRIPTION 11 LEUKERAN (chlorambucil) was first synthesized by Everett et al. It is a bifunctional 12 alkylating agent of the nitrogen mustard type that has been found active against selected human 13 neoplastic diseases. Chlorambucil is known chemically as 4-[bis(2- 14 chlorethyl)amino]benzenebutanoic acid and has the following structural formula: 15 16 17 18 Chlorambucil hydrolyzes in water and has a pKa of 5.8. 19 LEUKERAN (chlorambucil) is available in tablet form for oral administration. Each 20 film-coated tablet contains 2 mg chlorambucil and the inactive ingredients colloidal silicon 21 dioxide, hypromellose, lactose (anhydrous), macrogol/PEG 400, microcrystalline cellulose, red 22 iron oxide, stearic acid, titanium dioxide, and yellow iron oxide. 23 CLINICAL PHARMACOLOGY 24 Chlorambucil is rapidly and completely absorbed from the gastrointestinal tract. After single 25 oral doses of 0.6 to 1.2 mg/kg, peak plasma chlorambucil levels (Cmax) are reached within 1 hour 26 and the terminal elimination half-life (t½) of the parent drug is estimated at 1.5 hours. 27 Chlorambucil undergoes rapid metabolism to phenylacetic acid mustard, the major metabolite, 28 and the combined chlorambucil and phenylacetic acid mustard urinary excretion is extremely 29 low — less than 1% in 24 hours. In a study of 12 patients given single oral doses of 0.2 mg/kg of 30 LEUKERAN, the mean dose (12 mg) adjusted (± SD) plasma chlorambucil Cmax was 31 492 ± 160 ng/mL, the AUC was 883 ± 329 ng●h/mL, t½ was 1.3 ± 0.5 hours, and the tmax was 32 0.83 ± 0.53 hours.
    [Show full text]
  • Chemotherapy in Advanced Ovarian Cancer: an Overview of Randomised Clinical Trials BMJ: First Published As 10.1136/Bmj.303.6807.884 on 12 October 1991
    Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials BMJ: first published as 10.1136/bmj.303.6807.884 on 12 October 1991. Downloaded from Advanced Ovarian Cancer Trialists Group Abstract cytotoxic drugs, usually doxorubicin and cyclophos- Objectives-To consider the role of platinum and phamide with or without hexamethylmelamine.45 the relative merits of single agent and combination When, however, doubt was cast on the effectiveness chemotherapy in the treatment of advanced ovarian of doxorubicin by both randomised phase III trials6-8 cancer. and phase II studies in patients not responding to Design-Formal quantitative overview using cisplatin9 several major centres adopted cisplatin plus updated individual patient data from all available cyclophosphamide as standard. Furthermore, when randomised trials (published and unpublished). other trials failed to find significant survival differences Subjects-8139 patients (6408 deaths) included in between single agent cisplatin and cisplatin in combi- 45 different trials. nation with other drugs'0 some centres reverted to Results-No firm conclusions could be reached. using single agent platinum as routine first line treat- Nevertheless, the results suggest that in terms of ment. Recently a large number oftrials have compared survival immediate platinum based treatment was cisplatin with its less nephrotoxic and neurotoxic better than non-platinum regimens (overall relative analogue carboplatin, and although follow up times risk 0-93; 95% confidence interval 0-83 to 1-05); were often short, many institutions have now adopted platinum in combination was better than single agent carboplatin as standard. platinum when used in the same dose (overall Currently it is unclear what constitutes optimal relative risk 0-85; 0*72 to 1-00); and cisplatin and chemotherapy for advanced disease and treatment carboplatin were equally effective (overall relative strategies vary both nationally and internationally.
    [Show full text]
  • Anticancer Drug Discovery from Microbial Sources: the Unique Mangrove Streptomycetes
    molecules Review Anticancer Drug Discovery from Microbial Sources: The Unique Mangrove Streptomycetes Jodi Woan-Fei Law 1, Lydia Ngiik-Shiew Law 2, Vengadesh Letchumanan 1 , Loh Teng-Hern Tan 1, Sunny Hei Wong 3, Kok-Gan Chan 4,5,* , Nurul-Syakima Ab Mutalib 6,* and Learn-Han Lee 1,* 1 Novel Bacteria and Drug Discovery (NBDD) Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia; [email protected] (J.W.-F.L.); [email protected] (V.L.); [email protected] (L.T.-H.T.) 2 Monash Credentialed Pharmacy Clinical Educator, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia; [email protected] 3 Li Ka Shing Institute of Health Sciences, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, China; [email protected] 4 Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia 5 International Genome Centre, Jiangsu University, Zhenjiang 212013, China 6 UKM Medical Molecular Biology Institute (UMBI), UKM Medical Centre, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia * Correspondence: [email protected] (K.-G.C.); [email protected] (N.-S.A.M.); [email protected] (L.-H.L.) Academic Editor: Owen M. McDougal Received: 8 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Worldwide cancer incidence and mortality have always been a concern to the community. The cancer mortality rate has generally declined over the years; however, there is still an increased mortality rate in poorer countries that receives considerable attention from healthcare professionals.
    [Show full text]
  • B. Package Leaflet
    B. PACKAGE LEAFLET 1 Package Leaflet: Information for the User Chlorambucil 2 mg tablets chlorambucil Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions ask your doctor or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Chlorambucil is and what it is used for 2. What you need to know before you take Chlorambucil 3. How to take Chlorambucil 4. Possible side effects 5. How to store Chlorambucil 6. Contents of the pack and other information 1. What Chlorambucil is and what it is used for Chlorambucil contains a medicine called chlorambucil. This belongs to a group of medicines called cytotoxics (also called chemotherapy). Chlorambucil is used to treat some types of cancer and certain blood problems. It works by reducing the number of abnormal cells your body makes. Chlorambucil is used for: - Hodgkin's disease and Non-Hodgkin’s Lymphoma. Together, these form a group of diseases called lymphomas. They are cancers formed from cells of the lymphatic system. - Chronic lymphocytic leukaemia. A type of white blood cell cancer where the bone marrow produces a large number of abnormal white cells.
    [Show full text]
  • Cytostatics As Hazardous Chemicals in Healthcare
    REVIEW PAPER International Journal of Occupational Medicine and Environmental Health 2019;32(2):141 – 159 https://doi.org/10.13075/ijomeh.1896.01248 CYTOSTATICS AS HAZARDOUS CHEMICALS IN HEALTHCARE WORKERS’ ENVIRONMENT ANNA PAŁASZEWSKA-TKACZ, SŁAWOMIR CZERCZAK, KATARZYNA KONIECZKO, and MAŁGORZATA KUPCZEWSKA-DOBECKA Nofer Institute of Occupational Medicine, Łódź, Poland Department of Chemical Safety Abstract Cytostatics not only induce significant side-effects in patients treated oncologically but also pose a threat to the health of occupationally exposed healthcare workers: pharmacists, physicians, nurses and other personnel. Since the 1970s numerous reports from various countries have documented the contamination of working areas with cytostatics and the presence of drugs/metabolites in the urine or blood of healthcare employees, which di- rectly indicates the occurrence of occupational exposure to these drugs. In Poland the significant scale of occupational exposure to cytostatics is also confirmed by the data collected in the central register of occupational carcinogens/mutagens kept by the Nofer Institute of Occupational Medicine. The assessment of occupational exposure to cytostatics and health risks constitutes employers’ obligation. Unfortunately, the assessment of occu- pational risk resulting from exposure to cytostatics raises a number of concerns. Provisions governing the problem of workers’ health protection are not unequivocal because they derive from a variety of law areas, especially in a matter of hazard classification and safety data sheets for cytostatics. Moreover, no legally binding occupational exposure limits have been set for cytostatics or their active compounds, and analytical methods for these substances airborne and biological concentrations are lacking. Consequently, the correct assessment of occupational exposure to cytostatics, the eval- uation of health hazards and the development of the proper preventive strategy appear difficult.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Male Genital Cancers in the US in 2015 Frequency of Types
    5/22/2015 Male Genital Cancers in Germ Cell Tumors of the Testis the US in 2015 Pathology, Immunohistochemistry, and the Often Confusing Estimated Number Site Appearance of Their Metastases of Cases Prostate 220,800 Charles Zaloudek, MD Bladder 56,320 Department of Pathology Kidney 38,270 UCSF Testis 8430 Germ Cell Tumors of the Testis Frequency of Types Intratubular Germ Cell Neoplasia, Unclassified (IGCNU) Intratubular Germ Cell Neoplasia, Specific Types • Seminoma is the Tumor Type % Seminoma most common pure type Spermatocytic Seminoma Mixed GCT 78 Embryonal Carcinoma • Mixed germ cell Embryonal Yolk Sac Tumor tumor is the most 16 Choriocarcinoma common CA Other Trophoblastic Tumors nonseminomatous Teratoma 5 Teratoma germ cell tumor Yolk Sac 2 Mixed Germ Cell Tumor Tumor Calgary, Canada Mod Pathol 2013; 26: 579-586 1 5/22/2015 Intratubular Germ Cell Neoplasia (Carcinoma in Situ) • Precursor of most invasive germ cell tumors • Most likely in high risk patients; found in <1% of the normal population • Thought to be established in the fetus at the time the gonads develop • Switched on at puberty • Lacks 12p abnormalities found in invasive tumors • 50% develop invasive germ cell tumor by 5 years, 70% by 7 years Advances in Anatomic Pathology 2015; 22 (3): 202-212 I had a couple of previous papers returned from American journals, which for a long time did not appreciate the existence of a CIS pattern. However, even there, CIS is now officially recognized…. 2002 2 5/22/2015 The Background IGCNU IGCNU – OCT4 3 5/22/2015 IGCNU – SALL4 IGCNU – CD117 IGCNU – Pagetoid Spread to the Rete Testis Treatment of IGCNU • Unilateral: Orchiectomy • Bilateral: Low dose radiation – Prevents development of invasive germ cell tumor – Causes sterility 4 5/22/2015 Staging Testicular Tumors Clinical Stage I • Limited to testis and epididymis.
    [Show full text]
  • Non-Gestational Choriocarcinoma of the Ovary Complicated by Dysgerminoma: a Case Report
    6 Case Report Page 1 of 6 Non-gestational choriocarcinoma of the ovary complicated by dysgerminoma: a case report Chi Zhang1,2,3, Yangmei Shen1,2 1Department of Pathology, West China Second University Hospital of Sichuan University, Chengdu, China; 2Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, China; 3The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, China Correspondence to: Yangmei Shen. Department of Pathology, West China Second University Hospital of Sichuan University, Chengdu 610041, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, China. Email: [email protected]. Abstract: To report a case of non-gestational ovarian choriocarcinoma complicated by dysgerminoma and summarize its clinical manifestations, pathological features, treatment, and prognosis. The clinical manifestations, histomorphological features, and immunohistochemical staining findings of a patient with choriocarcinoma complicated by dysgerminoma were recorded. Computed tomography and vaginal color Doppler ultrasound in the outpatient department of our hospital showed that there were large, cystic or solid masses in the pelvic and abdominal cavities, which were considered to be malignant tumors originating from adnexa. Extensive hemorrhage and necrosis were seen in tumor tissues, which were composed of two tumor components: one tumor component contained cytotrophoblasts and syncytiotrophoblasts, and had no placental villous tissue; the other tumor component consisted of medium-sized, round or polygonal cells. Germ cell tumors were considered based on the histological morphological features of the HE-stained slices.
    [Show full text]
  • Persistent Gestational Trophoblastic Disease Is Potentially Fatal, but the Majority of Patients Are Cured with Chemotherapy
    British Journal of Cancer (2000) 82(9), 1547–1552 © 2000 Cancer Research Campaign DOI: 10.1054/ bjoc.2000.1176, available online at http://www.idealibrary.com on Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease LS Dobson, PC Lorigan, RE Coleman and BW Hancock Gestational Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK Summary Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis.
    [Show full text]